Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease

Vaccine

Volumn 27, Issue 24, 2009, Pages 3201-3208

  El Attar, L ^a   Oliver, S L ^a   Mackie, A ^a   Charpilienne, A ^b   Poncet, D ^b   Cohen, J ^b   Bridger, J C ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Neutralizing antigens; PCPP; Pig model; Protection; Rotavirus; Virus like particles; VLPs

Indexed keywords

LIVE VACCINE; ROTAVIRUS LIKE PARTICLE VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN ROTAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RABBIT; ROTAVIRUS; SWINE; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CATTLE; DISEASE MODELS, ANIMAL; RNA-BINDING PROTEINS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SWINE; VACCINATION; VIRAL NONSTRUCTURAL PROTEINS; VIRION;

EID: 67349199167     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.043     Document Type: Article

References (51)

1. Bresee J.S., Glass R.I., Ivanoff B., and Gentsch J.R. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 17 May (18) (1999) 2207-2222
2. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., and Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9 May (5) (2003) 565-572
3. Parashar U.D., Gibson C.J., Bresse J.S., and Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 February (2) (2006) 304-306
4. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.A., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 368 July (9532) (2006) 323-332
5. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48(November (43)):1007.
6. Theil K. Group A rotaviruses. In: Saif L.J., and Theil K.W. (Eds). Viral diarrheas of man and animals (1990), CRC Press, Boca Raton, FL 35-72
7. Isegawa Y., Nakagomi O., Nakagomi T., and Ueda S. A VP4 sequence highly conserved in human rotavirus strain AU-1 and feline rotavirus strain FRV-1. J Gen Virol 73 August (Pt 8) (1992) 1939-1946
8. Matthijnssens J., Rahman M., Martella V., Xuelei Y., De Vos S., De Leener K., et al. Full genomic analysis of human rotavirus strain B4106 and lapine rotavirus strain 30/96 provides evidence for interspecies transmission. J Virol 80 April (8) (2006) 3801-3810
9. Nakagomi O., Kaga E., and Nakagomi T. Human rotavirus strain with unique VP4 neutralization epitopes as a result of natural reassortment between members of the AU-1 and Wa genogroups. Arch Virol 127 1-4 (1992) 365-371
10. Park S.H., Saif L.J., Jeong C., Lim G.K., Park S.I., Kim H.H., et al. Molecular characterization of novel G5 bovine rotavirus strains. J Clin Microbiol 44 November (11) (2006) 4101-4112
11. Agnello D., Herve C.A., Lavaux A., Darniot M., Guillon P., Charpilienne A., et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 80 April (8) (2006) 3823-3832
12. Azevedo M.S., Yuan L., Iosef C., Chang K.O., Kim Y., Nguyen T.V., et al. Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. Clin Diagn Lab Immunol 11 January (1) (2004) 12-20
13. Blutt S.E., Warfield K.L., O'Neal C.M., Estes M.K., and Conner M.E. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 24 February (8) (2006) 1170-1179
14. Charpilienne A., Nejmeddine M., Berois M., Parez N., Neumann E., Hewat E., et al. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem 276 August (31) (2001) 29361-29367
15. Crawford S.E., Estes M.K., Ciarlet M., Barone C., O'Neal C.M., Cohen J., et al. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 73 June (6) (1999) 4813-4822
16. Gonzalez A.M., Nguyen T.V., Azevedo M.S., Jeong K., Agarib F., Iosef C., et al. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. Clin Exp Immunol 135 March (3) (2004) 361-372
17. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17 7-8 (1999) 1005-1013
18. Nguyen T.V., Iosef C., Jeong K., Kim Y., Chang K.O., Lovgren-Bengtsson K., et al. Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs. Vaccine 21 September (25-26) (2003) 4059-4070
19. O'Neal C.M., Clements J.D., Estes M.K., and Conner M.E. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 72 April (4) (1998) 3390-3393
20. O'Neal C.M., Crawford S.E., Estes M.K., and Conner M.E. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71 November (11) (1997) 8707-8717
21. Parez N., Fourgeux C., Mohamed A., Dubuquoy C., Pillot M., Dehee A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80 February (4) (2006) 1752-1761
22. Yuan L., Geyer A., Hodgins D.C., Fan Z., Qian Y., Chang K.O., et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol 74 October (19) (2000) 8843-8853
23. Yuan L., Iosef C., Azevedo M.S., Kim Y., Qian Y., Geyer A., et al. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. J Virol 75 October (19) (2001 Oct) 9229-9238
24. Istrate C., Hinkula J., Charpilienne A., Poncet D., Cohen J., Svensson L., et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 26 August (35) (2008) 4594-4601
25. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramig R.F., Estes M.K., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 72 November (11) (1998) 9233-9246
26. Conner M.E., Crawford S.E., Barone C., and Estes M.K. Rotavirus vaccine administered parenterally induces protective immunity. J Virol 67 November (11) (1993) 6633-6641
27. Crawford S.E., Labbe M., Cohen J., Burroughs M.H., Zhou Y.J., and Estes M.K. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68 September (9) (1994) 5945-5952
28. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 December (11) (2006) 1459-1466
29. Andrew M.E., Boyle D.B., Coupar B.E., Reddy D., Bellamy A.R., and Both G.W. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea. Vaccine 10 3 (1992) 185-191
30. Clark H.F., Offit P.A., Ellis R.W., Krah D., Shaw A.R., Eiden J.J., et al. WC3 reassortant vaccines in children. Arch Virol Suppl 12 (1996) 187-198
31. Hoshino Y., Saif L.J., Sereno M.M., Chanock R.M., and Kapikian A.Z. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol 62 March (3) (1988) 744-748
32. Matsui S.M., Offit P.A., Vo P.T., Mackow E.R., Benfield D.A., Shaw R.D., et al. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J Clin Microbiol 27 April (4) (1989) 780-782
33. Ward R.L., Knowlton D.R., Greenberg H.B., Schiff G.M., and Bernstein D.I. Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus. J Virol 64 June (6) (1990) 2687-2691
34. Ward R.L., McNeal M.M., Sander D.S., Greenberg H.B., and Bernstein D.I. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol 67 January (1) (1993) 464-468
35. Bridger J.C., Burke B., Beards G.M., and Desselberger U. The pathogenicity of two porcine rotaviruses differing in their in vitro growth characteristics and genes 4. J General Virol 73 November (Pt 11) (1992 Nov) 3011-3015
36. Choi A.H., McNeal M.M., Flint J.A., Basu M., Lycke N.Y., Clements J.D., et al. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20 March (13-14) (2002) 1733-1740
37. Johansson E., Istrate C., Charpilienne A., Cohen J., Hinkula J., Poncet D., et al. Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles. Vaccine 26 February (6) (2008) 778-785
38. Istrate C., Douagi I., Charpilienne A., McInerney G.M., Hidmark A., Johansen K., et al. Bone marrow dendritic cells internalize live RF-81 bovine rotavirus and rotavirus-like particles (RF 2/6-GFP-VLP and RF 8*2/6/7-VLP) but are only activated by live bovine rotavirus. Scand J Immunol 65 June (6) (2007) 494-502
39. Payne L.G., Jenkins S.A., Andrianov A., and Roberts B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 6 (1995) 473-493
40. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16 January (1) (1998) 92-98
41. Lu Y., Salvato M.S., Pauza C.D., Li J., Sodroski J., Manson K., et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol 12 June (2) (1996) 99-106
42. Bridger J.C., and Brown J.F. Antigenic and pathogenic relationships of three bovine rotaviruses and a porcine rotavirus. J Gen Virol 65 July (Pt 7) (1984) 1151-1158
43. Bridger J.C., Tauscher G.I., and Desselberger U. Viral determinants of rotavirus pathogenicity in pigs: evidence that the fourth gene of a porcine rotavirus confers diarrhea in the homologous host. J Virol 72 August (8) (1998) 6929-6931
44. Varshney K.C., Bridger J.C., Parsons K.R., Cook R., Teucher J., and Hall G.A. The lesions of rotavirus infection in 1- and 10-day-old gnotobiotic calves. Vet Pathol 32 November (6) (1995) 619-627
45. Andres I., Rodriguez-Diaz J., Buesa J., and Zueco J. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice. Biotechnol Bioeng 93 January (1) (2006) 89-98
46. Monnier N., Higo-Moriguchi K., Sun Z.Y., Prasad B.V., Taniguchi K., and Dormitzer P.R. High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain. J Virol 80 February (3) (2006) 1513-1523
47. Choi A.H., Basu M., McNeal M.M., Clements J.D., and Ward R.L. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol 73 September (9) (1999) 7574-7581
48. Burns J.W., Siadat-Pajouh M., Krishnaney A.A., and Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science (New York, NY) 272 April (5258) (1996) 104-107
49. Bridger J.C., and Oldham G. Avirulent rotavirus infections protect calves from disease with and without inducing high levels of neutralizing antibody. J General Virol 68 September (Pt 9) (1987) 2311-2317
50. Azevedo M.S., Yuan L., Pouly S., Gonzales A.M., Jeong K.I., Nguyen T.V., et al. Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus. J Virol 80 January (1) (2006) 372-382
51. Jiang B., Gentsch J.R., and Glass R.I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26 December (52) (2008) 6754-6758